324 related articles for article (PubMed ID: 28756410)
1. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
[TBL] [Abstract][Full Text] [Related]
2. One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease.
Najafian B; Tøndel C; Svarstad E; Sokolovkiy A; Smith K; Mauer M
PLoS One; 2016; 11(4):e0152812. PubMed ID: 27081853
[TBL] [Abstract][Full Text] [Related]
3. Migalastat: A Review in Fabry Disease.
McCafferty EH; Scott LJ
Drugs; 2019 Apr; 79(5):543-554. PubMed ID: 30875019
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss.
Najafian B; Tøndel C; Svarstad E; Gubler MC; Oliveira JP; Mauer M
J Am Soc Nephrol; 2020 Apr; 31(4):865-875. PubMed ID: 32127409
[TBL] [Abstract][Full Text] [Related]
5. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
Germain DP; Hughes DA; Nicholls K; Bichet DG; Giugliani R; Wilcox WR; Feliciani C; Shankar SP; Ezgu F; Amartino H; Bratkovic D; Feldt-Rasmussen U; Nedd K; Sharaf El Din U; Lourenco CM; Banikazemi M; Charrow J; Dasouki M; Finegold D; Giraldo P; Goker-Alpan O; Longo N; Scott CR; Torra R; Tuffaha A; Jovanovic A; Waldek S; Packman S; Ludington E; Viereck C; Kirk J; Yu J; Benjamin ER; Johnson F; Lockhart DJ; Skuban N; Castelli J; Barth J; Barlow C; Schiffmann R
N Engl J Med; 2016 Aug; 375(6):545-55. PubMed ID: 27509102
[TBL] [Abstract][Full Text] [Related]
7. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.
Giugliani R; Waldek S; Germain DP; Nicholls K; Bichet DG; Simosky JK; Bragat AC; Castelli JP; Benjamin ER; Boudes PF
Mol Genet Metab; 2013 May; 109(1):86-92. PubMed ID: 23474038
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort.
Nowak A; Huynh-Do U; Krayenbuehl PA; Beuschlein F; Schiffmann R; Barbey F
J Inherit Metab Dis; 2020 Mar; 43(2):326-333. PubMed ID: 31449323
[TBL] [Abstract][Full Text] [Related]
9. Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.
Schiffmann R; Bichet DG; Jovanovic A; Hughes DA; Giugliani R; Feldt-Rasmussen U; Shankar SP; Barisoni L; Colvin RB; Jennette JC; Holdbrook F; Mulberg A; Castelli JP; Skuban N; Barth JA; Nicholls K
Orphanet J Rare Dis; 2018 Apr; 13(1):68. PubMed ID: 29703262
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.
Narita I; Ohashi T; Sakai N; Hamazaki T; Skuban N; Castelli JP; Lagast H; Barth JA
Clin Exp Nephrol; 2020 Feb; 24(2):157-166. PubMed ID: 31889231
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.
Feldt-Rasmussen U; Hughes D; Sunder-Plassmann G; Shankar S; Nedd K; Olivotto I; Ortiz D; Ohashi T; Hamazaki T; Skuban N; Yu J; Barth JA; Nicholls K
Mol Genet Metab; 2020; 131(1-2):219-228. PubMed ID: 33012654
[TBL] [Abstract][Full Text] [Related]
12. Inter-assay variability influences migalastat amenability assessments among Fabry disease variants.
Oommen S; Zhou Y; Meiyappan M; Gurevich A; Qiu Y
Mol Genet Metab; 2019 May; 127(1):74-85. PubMed ID: 31036492
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study.
Germain DP; Nicholls K; Giugliani R; Bichet DG; Hughes DA; Barisoni LM; Colvin RB; Jennette JC; Skuban N; Castelli JP; Benjamin E; Barth JA; Viereck C
Genet Med; 2019 Sep; 21(9):1987-1997. PubMed ID: 30723321
[TBL] [Abstract][Full Text] [Related]
14. A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease.
Najafian B; Silvestroni A; Sokolovskiy A; Tøndel C; Svarstad E; Obrisca B; Ismail G; Holida MD; Mauer M
Kidney Int; 2022 Jul; 102(1):173-182. PubMed ID: 35483528
[TBL] [Abstract][Full Text] [Related]
15. Chaperone Therapy in Fabry Disease.
Weidemann F; Jovanovic A; Herrmann K; Vardarli I
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163813
[TBL] [Abstract][Full Text] [Related]
16. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
[TBL] [Abstract][Full Text] [Related]
17. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients.
Skrunes R; Svarstad E; Kampevold Larsen K; Leh S; Tøndel C
Nephrol Dial Transplant; 2017 May; 32(5):807-813. PubMed ID: 27190352
[TBL] [Abstract][Full Text] [Related]
18. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
[TBL] [Abstract][Full Text] [Related]
19. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
20. Assessment of plasma lyso-Gb
Bichet DG; Aerts JM; Auray-Blais C; Maruyama H; Mehta AB; Skuban N; Krusinska E; Schiffmann R
Genet Med; 2021 Jan; 23(1):192-201. PubMed ID: 32994552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]